Synthesis of copanlisib and its dihydrochloride salt

Patent metadata

Field	Value
Publication number	US-10035803-B2
Application number	US-201515524478-A
Country	US
Kind code	B2
Filing date	Nov 5, 2015
Priority date	Nov 7, 2014
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.

First claim

The invention claimed is:

1. A method of preparing copanlisib (7):

comprising the following steps:
step A6:
reacting a compound of formula (6):

with a compound of formula (6b):

in the presence of a catalyst and a coupling agent, to provide copanlisib (7):

wherein the compound of formula (6):

is prepared by the following step A5:
reacting a compound of formula (5):

with cyanogen bromide as annelating agent,
to provide the compound of formula (6);
wherein the compound of formula (5):

is prepared by the following step A4:
reacting a compound of formula (4):

with hydrogen in the presence of a 5% palladium/1% iron catalyst on carbon which is water-wetted, in a solvent, to provide the compound of formula (5).

2. The method according to claim 1 , wherein the compound of formula (4):

is prepared by the following step A3:
reacting a compound of formula (3):

with ethylenediamine to provide the compound of formula (4).

3. The method according to claim 2 , wherein the compound of formula (3):

is prepared by the following step A2:
reacting a compound of formula (2):

with a compound of formula (2a):

to provide the compound of formula (3).

4. The method according to claim 3 , wherein the compound of formula (2):

is prepared by the following step A1:
a) reacting a compound of formula (1):

with nitric acid and sulphuric acid to form a reaction mixture, and
b) adding a base to the reaction mixture of a)
to provide the compound of formula (2).

5. The method according to claim 1 , wherein the compound of formula (6b):

is prepared by the following step A7:
a) reacting a compound of formula (6a):

with a base, with heating, to form a reaction mixture;
b) cooling the reaction mixture from a), and adding methyl formate to the resulting reaction mixture;
c) adding guanidine hydrochloride to the reaction mixture from b), followed by heating;
d) adding water and an aqueous solution of a base to the reaction mixture from c), followed by heating;
e) adding an aqueous solution of a mineral acid to the reaction mixture from d);
f) adding an amine to the reaction mixture from e), and filtering off a resulting solid;
g) adding an aqueous solution of a strong base to the reaction mixture from f); and
h) adding an aqueous solution of a mineral acid to the reaction mixture from g),
to provide the compound of formula (6b):

6. The method according to claim 1 , further comprising the following step A8:
reacting copanlisib (7):

with hydrogen chloride
to provide copanlisib dihydrochloride (8):

7. The method according to claim 1 , wherein copanlisib (7) is prepared by the following steps shown in Reaction Scheme 3:

8. A compound selected from the group consisting of:

9. The method of claim 1 , wherein the catalyst of step A6 is N,N-dimethyl-4-aminopyridine.

10. The method of claim 1 , wherein the coupling agent of step A6 is N-[3-(dimethylamino)propyl]-N′-ethylcarbodiimide hydrochloride.

11. The method of claim 1 , wherein step A5 is carried out in the presence of a base, and wherein the base is triethylamine.

12. The method of claim 3 , wherein step A2 is carried out in the presence of a base, and wherein the base is potassium carbonate.

13. The method of claim 4 , wherein the base of step A1 b) is potassium carbonate.

14. The method of claim 5 , wherein the base of step A7 a) is sodium methoxide.

15. The method of claim 5 , wherein the base of step A7 d) is sodium hydroxide.

16. The method of claim 5 , wherein the mineral acid of step A7 e) is hydrochloric acid.

17. The method of claim 5 , wherein the amine of step A7 f) is dicyclohexylamine.

18. The method of claim 5 , wherein the strong base of step A7 g) is sodium hydroxide.

19. The method of claim 5 , wherein the mineral acid of step A7 h) is hydrochloric acid.

20. The method of claim 2 , wherein step A3 is carried out in the presence of N-bromosuccinimide.

21. The method of claim 1 , wherein step A6 is carried out in the presence of a solvent, and wherein the solvent is N,N-dimethylformamide.

22. The method of claim 1 , wherein step A5 is carried out in the presence of a solvent, and wherein the solvent is dichloromethane.

23. The method of claim 1 , wherein the solvent of step A4 is methanol.

24. The method of claim 2 , wherein step A3 is carried out in the presence of a solvent, and wherein the solvent is dichloromethane.

25. The method of claim 3 , wherein step A2 is carried out in the presence of a solvent, and wherein the solvent is acetonitrile.

Assignees

• Bayer Pharma AG

Inventors

• Peters Jan-Georg
• Stiehl Jürgen
• Lovis Kai

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D233/24 Primary

  Radicals substituted by nitrogen atoms not forming part of a nitro radical · CPC title

• C07D295/088

  to an acyclic saturated chain · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title